DE69942485D1 - Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems - Google Patents

Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems

Info

Publication number
DE69942485D1
DE69942485D1 DE69942485T DE69942485T DE69942485D1 DE 69942485 D1 DE69942485 D1 DE 69942485D1 DE 69942485 T DE69942485 T DE 69942485T DE 69942485 T DE69942485 T DE 69942485T DE 69942485 D1 DE69942485 D1 DE 69942485D1
Authority
DE
Germany
Prior art keywords
complement system
high affinity
protein
nuclear acid
acid surfaces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942485T
Other languages
English (en)
Inventor
Gregory Biesecker
Larry Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/163,025 external-priority patent/US6395888B1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DE69942485D1 publication Critical patent/DE69942485D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
DE69942485T 1998-02-12 1999-02-05 Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems Expired - Lifetime DE69942485D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/023,228 US6140490A (en) 1996-02-01 1998-02-12 High affinity nucleic acid ligands of complement system proteins
US09/163,025 US6395888B1 (en) 1996-02-01 1998-09-29 High affinity nucleic acid ligands of complement system proteins
PCT/US1999/002597 WO1999041271A1 (en) 1998-02-12 1999-02-05 High affinity nucleic acid ligands of complement system proteins

Publications (1)

Publication Number Publication Date
DE69942485D1 true DE69942485D1 (de) 2010-07-22

Family

ID=42244869

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942485T Expired - Lifetime DE69942485D1 (de) 1998-02-12 1999-02-05 Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems

Country Status (6)

Country Link
US (1) US6140490A (de)
JP (2) JP4698832B2 (de)
AT (1) ATE470712T1 (de)
DE (1) DE69942485D1 (de)
DK (1) DK1062226T3 (de)
ES (1) ES2345470T3 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6451588B1 (en) * 2000-06-30 2002-09-17 Pe Corporation (Ny) Multipartite high-affinity nucleic acid probes
DK1401853T3 (da) 2001-05-25 2010-11-01 Univ Duke Modulatorer af farmakologiske midler
DE10226011A1 (de) * 2002-06-12 2004-01-08 Aventis Pharma Deutschland Gmbh HTS-fähiges Verfahren und Testsystem zur Ermittlung der Wechselwirkung zwischen c-reaktivem Protein und an C-reaktives Protein bindenden Komponenten
US20030232394A1 (en) * 2002-06-12 2003-12-18 Aventis Pharma Deutschland Gmbh High throughput screening method and assay system for determining the interaction between C-reactive protein and components binding to it
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP3385384B1 (de) * 2004-02-12 2020-04-08 Archemix LLC Aptamer-therapeutika zur behandlung von mit dem komplementsystem in verbindung stehenden erkrankungen
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2005092308A2 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Neural tourniquet
JP2008525102A (ja) 2004-12-27 2008-07-17 ノース ショア−ロング アイランド ジューウィッシュ リサーチ インスティテュート 電気的な迷走神経刺激による炎症性障害の処置
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP1991275B1 (de) 2006-03-08 2014-11-05 Archemix LLC Komplementbindende aptamere und anti-c5-wirkstoffe zur behandlung von augenleiden
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2010059617A2 (en) 2008-11-18 2010-05-27 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
AU2010258792B2 (en) 2009-06-09 2015-07-02 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
CN103619405B (zh) 2011-05-09 2015-11-25 赛博恩特医疗器械公司 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活
CA2860806C (en) 2012-01-10 2020-10-20 Noxxon Pharma Ag New c5a binding nucleic acids
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
NO2718257T3 (de) * 2014-05-30 2018-04-14
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CN108934169A (zh) 2016-01-20 2018-12-04 维特里萨医疗公司 用于抑制因子d的组合物和方法
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255A4 (de) 2016-01-20 2019-10-16 Setpoint Medical Corporation Implantierbare mikrostimulatoren und induktive ladesysteme
CN114904142A (zh) 2016-01-20 2022-08-16 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
EP3668402A4 (de) 2017-08-14 2021-05-19 Setpoint Medical Corporation Vagusnervstimulationsvorscreening-test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4434585A (en) * 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
WO1989006694A1 (en) * 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5476766A (en) * 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
CA2104698A1 (en) * 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
US5428149A (en) * 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
ATE468396T1 (de) * 1996-02-01 2010-06-15 Gilead Sciences Inc Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems
AU2994997A (en) * 1996-05-07 1997-11-26 T Cell Sciences, Inc. Aptamers for complement protein c3b

Also Published As

Publication number Publication date
JP2010187687A (ja) 2010-09-02
US6140490A (en) 2000-10-31
ES2345470T3 (es) 2010-09-23
JP4698832B2 (ja) 2011-06-08
DK1062226T3 (da) 2010-10-11
JP2002503455A (ja) 2002-02-05
ATE470712T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
DE69942485D1 (de) Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems
CA2320100A1 (en) High affinity nucleic acid ligands of complement system proteins
EP1975172A3 (de) Hochaffine TGFß-Nukleinsäureliganden und -inhibitoren
DE69636656D1 (de) Oligonukleotidliganden mit hoher affinität für pdgf
DE69736598D1 (de) Ribonukleaseresistente rna präparation und seine verwendung
IL145337A0 (en) Process for partitioning of proteins
DE69403642T2 (de) 7-deazapurin modifizierte oligonukleotide
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
DK0743949T3 (da) Fremgangsmåde til fremstilling af endotoksinfrie eller endotoksinfattige nukleinsyrer og/eller oligonukleotider til gentera
PT1232502E (pt) Particulas de vidro magneticas, metodo para a sua preparacao e suas utilizacoes
DE59510976D1 (de) Verfahren zur isolierung von zellinhaltsstoffen, wie nucleinsäuren, aus natürlichen quellen
ES2176484T3 (es) Bancos de proteinas/(poli)peptidos.
DE69840966D1 (de) Homolog NL6 des Tie Rezeptor Tyrosinekinase Liganden
ATE342969T1 (de) Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen
ATE331034T1 (de) Samenstrenung resistenz
DK0981630T3 (da) Polypeptider med prolyldipeptidylaminopeptidaseaktivitet og nukleinsyrer, der koder for samme
PT668931E (pt) Ligandos de acidos nucleicos e metodos para producao dos mesmos
DE69932599D1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE280947T1 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
HK1049185A1 (zh) 可改螢光蛋白
FI961202A (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
DK1082423T3 (da) Cyclin E2-gener og -proteiner
EP0888374A4 (de) Nukleinsäureliganden mit hoher affinität für die proteine des komplementsystems
ATE212382T1 (de) Verfahren zur sequenzierung durch oligomerhybridisierung